|
|
-
有效防止肺巨噬细胞吸收纳米颗粒Effectively prevent lung macrophages from absorbing nanoparticles
-
给药一天后,约One day after administration, about 14%的聚乙二醇化纳米颗粒从肺部清除,而约37%的非聚乙二醇化颗粒被消除 of the pegylated nanoparticles are cleared from the lungs, while about 37% of the non-pegylated particles are eliminated
|
[45] |
|
-
The speed and degree of internalization of DOX细胞内化的速度和程度增加 cells increases
-
从DOX released from mPEG-DOX纳米颗粒释放的DOX在酸性环境中显着加速 nanoparticles is significantly accelerated in acidic environments
-
细胞毒性:Cytotoxicity: mPEG1K–DOX > 游离free DOX > mPEG2K–DOX ≫ mPEG5K–DOX
|
[46] |
|
|
[47] |
|
|
-
The diffusion rate of the CF粘液模型的扩散速率提高 mucus model was increased by a factor of 2.6倍
-
对粘蛋白的亲和力降低Decreased affinity for mucin
-
共轭纳米颗粒的细胞摄取增加Cell uptake by conjugated nanoparticles increased 3 倍-fold
|
[48] |
|
-
出色的肺分布Excellent lung distribution
-
聚乙二醇化纳米颗粒表现出优异的胶体稳定性Polyethylene glycolated nanoparticles exhibit excellent colloidal stability
-
40% PEG修饰的纳米颗粒表现出优异的转基因表达-modified nanoparticles exhibit excellent transgene expression
|
[1] |
|
|
|
[49] |
|
-
高封装效率High package efficiency ((70.89%))
-
SNEDDS配方表现出增加的粘液渗透性 formulations exhibit increased mucus permeability
-
保护蛋白质免受酶降解Protects proteins from enzymatic degradation
|
[50] |
-
由聚乳酸Lipid polymer hybrid nanoparticles consisting of a polylactic acid-乙醇酸(PLGA)核心和二棕榈酰磷脂酰胆碱(DPPC)脂质壳组成的脂质聚合物杂化纳米颗粒glycolic acid (PLGA) core and a dipalmitoylphosphatidylcholine (DPPC) lipid shell
-
Polyethylene glycol surface coating
|
|
[51] |
|
|
-
Levels of hypoxia-inducible factor (HIF)-1α, VEGF, phosphatidylinositol-3 kinase (PI3K) increased
-
Mucous glycoprotein expression (Muc5ac) in lung tissues was substantially decreased
|
[52] |
|
-
Gold nanoparticles clearly inhibited (70–100%) allergen-induced accumulation of inflammatory cells as well as the production of both pro-inflammatory cytokines and reactive oxygen species
-
Gold nanoparticles prevented airway hyper-reactivity, inflammation and lung remodeling
|
[53] |
|
|
-
Improved mucosal adhesion of thiolated nanoparticles
-
Ranking of particle adhesion ability: CS-TBA > PAA-Cys > CS > PAA
-
CS-TBA has 2-fold higher mucosal adhesion properties than PAA-Cys NP
|
[54] |
-
Sodium tripolyphosphate (TPP) as ionic crosslinker
-
Mannose-anchored N,N,N-trimethyl chitosan nanoparticles (TMC) doped with ethoxanthine (ETO) were prepared
|
-
The prepared Mn-TMC NPs had a particle size of 223.3 nm, a PDI of 0.490, a ζ potential of −19.1 mV, a drug loading of 76.26 ± 1.2%, and an encapsulation efficiency of 91.75 ± 0.88%
-
The pulmonary bioavailability of TMC-TPP NPs was 4.2 times higher than that of ETO suspension, while the pulmonary bioavailability of MnTMC-TPP NPs was 4.1 times higher than that of ETO suspension
|
[55] |
|
-
Absorption properties of polymers increase with the degree of quaternization
-
All these polymers led to a mild increase in mucus secretion at pH 4.40.
-
At pH 7.40, only highly quaternized TMC can increase nasal absorption of insulin
|
[56] |
|
|
-
Local albuterol retention in the lungs is more than three times higher than albuterol without HA
-
A reasonable in vitro lung deposition with a fine particle fraction of over 30%
-
Hyaluronic acid allows SAS to have extended release properties and prolong retention time in the lungs
-
The maximum plasma concentration decreased significantly from 2267.7 ng/mL to 566.38 ng/mL
|
[57] |
|
|
[58] |
|
-
Firstly, curcumin-PLGA NP was prepared
-
Multi-drug respirable particles (MP) were prepared with a matrix consisting of N-acetylcysteine (NAC) with antibiotics and the nanoparticles prepared above
|
-
The composite nanoparticles embedded with NAC showed strong mucus permeability after 15 min
-
NAC-loaded composite nanoparticles result in reduced TNF-α release
-
10 mM NAC reduced TNF-α and IL-8 by 45% and 58%, respectively
|
[59] |